SpyGlass Pharma Q3 2026 Results: Net Loss of $24.3M, Loss Widens
SpyGlass Pharma reported a net loss of $57.9 million for the nine months ended September 30, 2026, compared to $27.3 million in the prior year, driven by increased R&D and G&A expenses. The company significantly strengthened its balance sheet through an initial public offering and the conversion of preferred stock, ending the period with $208.7 million in cash and cash equivalents.
- Key figure
- Net loss $24.3M